A Study to Evaluate the Efficacy and Safety of X0002 Spray in Subjects With Osteoarthritis

NCT ID: NCT02067611

Last Updated: 2018-02-07

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 216 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-02-28
• Study Completion Date: 2016-04-30

Brief Summary

This is a phase 2, multicenter, randomized, double blind (with dose), placebo controlled, parallel group, proof of concept, and dose range finding study to evaluate the efficacy, safety, and PK of X0002 spray in adult subjects with clinically symptomatic mild to moderate OA of the knee.

Objectives of the study:

1. To evaluate the efficacy of X0002 spray compared to placebo for relief of knee pain in subjects with osteoarthritis (OA) of the knee;

2. To assess the safety and tolerability of multiple doses of X0002 when administered as a topical spray.

Detailed Description

This is a phase 2, multicenter, randomized, double blind (with dose), placebo controlled, parallel group, proof of concept, and dose range finding study to evaluate the efficacy, safety, and PK of X0002 spray in adult subjects with clinically symptomatic mild to moderate OA of the knee.

After a screening period of up to 3 weeks and radiographic evaluation of the target knee joint space, 225 subjects will be randomly assigned to 1 of 3 treatment groups in a 1:1:1 ratio with a 2:1 ratio of active:placebo within each treatment group in a 1:1:1 ratio with a 2:1 ratio of active:placebo within each treatment group (i.e., 2 subjects to active treatment and 1 subject to placebo):

Group A: low dose of X0002, twice daily (BID, approximately every 12 hours; n=50) or placebo (low dose), BID (approximately every 12 hours; n=25); Group B: middle dose of X0002, BID (approximately every 12 hours; n=50) or placebo , BID (approximately every 12 hours; n=25) ; Group C: High dose of X0002, BID (approximately every 12 hours; n=50) or placebo, BID (approximately every 12 hours; n=25) .

Safety and efficacy assessments will be performed at at 2, 4, 8, and 12 weeks of treatment.

Conditions

Osteoarthritis of the Knee

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

X0002

low dose, BID;middle dose, BID, or high dose, BID.

Group Type: EXPERIMENTAL

X0002

Intervention Type: DRUG

Parallel Assignment

Placebo

low dose, BID; middle dose, BID, or high dose, BID.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Parallel Assignment

Interventions

X0002

Parallel Assignment

Intervention Type: DRUG

Placebo

Parallel Assignment

Intervention Type: DRUG

Other Intervention Names

Active drug; Placebo powder

Eligibility Criteria

Inclusion Criteria

• A subject must be a male or female between 35 and 85 years of age, inclusive.
• A subject must have a body mass index (BMI) between 18.5 and 39.9 kg/m2, inclusive.
• A subject must have a diagnosis of idiopathic OA according to the American College of Rheumatology (ACR) clinical and radiographic criteria (knee pain, osteophytes, and at least one of the following: >50 years of age, morning stiffness lasting <30 minutes after getting up in the morning, or crepitus).
• A subject must have a Kellgren Lawrence Grade of 1 or 2 as determined by the Investigator or a local radiologist at Screening.
• A subject must have a history of clinically symptomatic mild to moderate OA of the knee for ≥6 months.
• A subject must have had knee pain while standing, walking, and/or on motion for at least 14 days during the month prior to Screening.
• A subject must have a knee pain score ≥40 mm and <90 mm on a 100 mm VAS (with or without analgesic medication) on at least 10 of the 14 days prior to randomization.
• A subject must be willing to discontinue any NSAIDs or other analgesic (eg, aspirin, acetaminophen) or potentially confounding concomitant treatments (eg, physiotherapy, acupuncture) starting 4 days before the administration of the first dose of study medication until completing participation in the study. (The use of ≤325 mg acetylsalicylic acid per day as cardiac prophylaxis is permitted.) The subject will be allowed to take rescue medication (acetaminophen) for pain during the study except during the 24 hours prior to Baseline (Day1), Week 2, Week 4, Week 8, Week 12/EOS, and Follow-up assessments.
• A subject must be willing to avoid unaccustomed physical activity (eg, starting a new weight lifting routine) for the duration of the study.

Exclusion Criteria

• A subject who has secondary OA of the knee or OA of lower limb joints other than the knee that, in the opinion of the Investigator, could interfere with pain and functional assessments related to the knee
• A subject who has OA of the knee with a Kellgren Lawrence Grade ≥3 as determined by the Investigator or a local radiologist at Screening
• A subject who has a history of total or partial knee replacement, arthroplasty, or other knee surgery on either knee
• A subject who has had significant injury, as judged by the Investigator, involving the target knee within the 6 months before Screening.
• A subject who has skin lesions or wounds on or near the knees to be treated at Screening or on Day 1 prior to the first administration of study medication
• A subject who has used opiates or corticosteroids within 30 days before Screening or who requires treatment with chronic opiates or corticosteroids
• A subject who has had intra articular injections of corticosteroids, hyaluronic acid, or viscosupplements (eg, Synvisc®) to a knee to be treated within the 3 months before Screening.
• A subject who has a history of significant hypersensitivity, intolerance, or allergy to ibuprofen, any NSAIDs, aspirin, or acetaminophen
• A subject who has had an active peptic ulceration in the 12 months prior to Screening or a history of gastrointestinal (GI) bleeding within 5 years of Screening
• A subject who has used an anticoagulant (except aspirin up to 325 mg/day for cardiac prophylaxis) in the month prior to Screening
• A subject who has positive results on fecal occult blood testing at Screening or on Day 1 prior to the first administration of study medication
• A subject who has a history of chronic inflammatory disease (such as rheumatoid arthritis, psoriatic arthritis, gouty arthritis), fibromyalgia, conditions that may affect the target joint (eg, osteonecrosis, chondrocalcinosis), or asthma.

• Minimum Eligible Age: 35 Years
• Maximum Eligible Age: 85 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Lina Xu

INDUSTRY

Sponsor Role: lead

Responsible Party

Lina Xu

Vice president

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Chongxi Yu, Ph.D.

Role: STUDY_CHAIR

Techfields Inc

Locations

Fiel Family & Sports Medicine/Clinical Research Advantage Inc

Tempe, Arizona, United States

Med Center

Carmichael, California, United States

Encompass Clinical Research

Spring Valley, California, United States

Diablo Clinical Research, Inc.

Walnut Creek, California, United States

New England Research Assoc.

Trumbull, Connecticut, United States

Clinical Research of South Florida

Coral Gables, Florida, United States

Avail Clinical Research, LLC

DeLand, Florida, United States

Health Awareness Inc.

Jupiter, Florida, United States

Suncoast Clinical Research, Inc

New Port Richey, Florida, United States

Columbus Regional Research Institute

Columbus, Georgia, United States

Clinical Trials Technology(CTT) Consultants, Inc.

Prairie Village, Kansas, United States

Healthcare Research Network

Hazelwood, Missouri, United States

Sundance Clinical Research, LLC

St Louis, Missouri, United States

New Mexico Clinical Research & Osteoporosis Center, Inc.

Albuquerque, New Mexico, United States

Hightop Medical Research

Cincinnati, Ohio, United States

Prestige Clinical Research, LLC

Franklin, Ohio, United States

Heritage Valley Medical Group

Beaver, Pennsylvania, United States

Altoona Center for Clinical Research

Duncansville, Pennsylvania, United States

Quality Research Inc

San Antonio, Texas, United States

Health Research of Hampton Roads, Inc

Newport News, Virginia, United States

Countries

United States

Other Identifiers

TF-X0002-21

Identifier Type: -

Identifier Source: org_study_id